Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy
These findings suggest the KRS may effectively stratify VTE risk and mortality in gastric cancer patients treated with ICIs.
Authors
- Cho‐Han Chiang (ORCID: https://orcid.org/0000-0002-5757-6161)
- Yu‐Sun Chang (ORCID: https://orcid.org/0000-0002-6457-3890)
- Ahmed Ashraf Morgan
- Lawrence W. Wu (ORCID: https://orcid.org/0000-0002-8013-1275)
- Jaeun Ahn (ORCID: https://orcid.org/0000-0002-1331-7854)
- Muhammad Fahimuddin
- Wing Fai Li
- Kuan-Yu Chi
- Yu‐Cheng Chang (ORCID: https://orcid.org/0000-0002-9634-8380)
- Junmin Song
Institutions
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- Eastern Virginia Medical School (US)
- Columbia University Irving Medical Center (US)
- Danbury Hospital (US)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-04-13
- DOI
- https://doi.org/10.1080/1750743x.2025.2501922
- Citations
- 2
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 4.01